ODG
ESPR

O'Dell Group’s Esperion Therapeutics ESPR Stock Holding History

O'Dell Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,500
Closed -$13.5K – 201
2023
Q4 		$13.5K Buy
+4,500
New +$5.84K ﹤0.01% 324
2023
Q3 		– Sell
-4,500
Closed -$6.25K – 185
2023
Q2 		$6.25K Buy
+4,500
New +$6.28K ﹤0.01% 377
2022
Q3 		– Sell
-261
Closed -$2K – 431
2022
Q2 		$2K Hold
261
– – ﹤0.01% 403
2022
Q1 		$1K Buy
+261
New +$1.12K ﹤0.01% 476

Other funds holding ESPR

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

O'Dell Group's ESPR Position: Q1 2024 in Review

O'Dell Group sold out of Esperion Therapeutics (ESPR) in Q1 2024, closing a stake of 4,500 shares — an estimated $13.5K sold.

O'Dell Group first reported a position in ESPR in Q1 2022 and held it in 4 quarters. The position peaked at $13.5K in Q4 2023. 153 funds tracked by Wall St. Rank hold ESPR as of Q1 2024.

  • O'Dell Group reported no remaining Esperion Therapeutics position as of Q1 2024 after selling out during the quarter.
  • O'Dell Group sold 4,500 Esperion Therapeutics shares in Q1 2024, an estimated $13.5K.
  • O'Dell Group first reported a position in Esperion Therapeutics in Q1 2022 and held it in 4 quarters.
  • O'Dell Group's Esperion Therapeutics position peaked at $13.5K in Q4 2023.
  • 153 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2024.

Based on O'Dell Group's 13F filing for Q1 2024, filed 7 May 2024.